LITTLE ROCK, Ark. (KTHV) - UAMS has partnered with a pharmaceutical company to help meth users fight their addictions.
InterveXion Therapeutics helped UAMS complete the first human safety study of a medication that reduces or prevents the euphoric rush that drug users crave by keeping methamphetamine in the bloodstream and out of the brain, where the drug exerts its most powerful effects.
The first phase over eight months showed that the drug had no serious side effects. The next steps involve a clinical safety trial with current meth users.
When it has received final approval, officials say the antibody will be given as an integral part of a methamphetamine user's complete treatment program, which consists of counseling and possibly other medications to reduce craving.